- Title
- C5b-9 Membrane Attack Complex Formation and Extracellular Vesicle Shedding in Barrett’s Esophagus and Esophageal Adenocarcinoma
- Creator
- Kolka, Cathryn M.; Webster, Julie; Wuethrich, Alain; Trau, Matt; Brosda, Sandra; Barbour, Andrew; Shah, Alok K.; Eslick, Guy D.; Clemons, Nicholas J.; Morgan, B. Paul; Hill, Michelle M.; Lepletier, Ailin; Winterford, Clay; Brown, Ian; Richards, Renee S.; Zelek, Wioleta M.; Cao, Yilang; Khamis, Ramlah; Shanmugasundaram, Karthik B.
- Relation
- Frontiers in Immunology Vol. 13, Issue 8 March 2022, no. 842023
- Publisher Link
- http://dx.doi.org/10.3389/fimmu.2022.842023
- Publisher
- Frontiers Research Foundation
- Resource Type
- journal article
- Date
- 2022
- Description
- The early complement components have emerged as mediators of pro-oncogenic inflammation, classically inferred to cause terminal complement activation, but there are limited data on the activity of terminal complement in cancer. We previously reported elevated serum and tissue C9, the terminal complement component, in esophageal adenocarcinoma (EAC) compared to the precursor condition Barrett’s Esophagus (BE) and healthy controls. Here, we investigate the level and cellular fates of the terminal complement complex C5b-9, also known as the membrane attack complex. Punctate C5b-9 staining and diffuse C9 staining was detected in BE and EAC by multiplex immunohistofluorescence without corresponding increase of C9 mRNA transcript. Increased C9 and C5b-9 staining were observed in the sequence normal squamous epithelium, BE, low- and high-grade dysplasia, EAC. C5b-9 positive esophageal cells were morphologically intact, indicative of sublytic or complement-evasion mechanisms. To investigate this at a cellular level, we exposed non-dysplastic BE (BAR-T and CP-A), high-grade dysplastic BE (CP-B and CP-D) and EAC (FLO-1 and OE-33) cell lines to the same sublytic dose of immunopurified human C9 (3 µg/ml) in the presence of C9-depleted human serum. Cellular C5b-9 was visualized by immunofluorescence confocal microscopy. Shed C5b-9 in the form of extracellular vesicles (EV) was measured in collected conditioned medium using recently described microfluidic immunoassay with capture by a mixture of three tetraspanin antibodies (CD9/CD63/CD81) and detection by surface-enhanced Raman scattering (SERS) after EV labelling with C5b-9 or C9 antibody conjugated SERS nanotags. Following C9 exposure, all examined cell lines formed C5b-9, internalized C5b-9, and shed C5b-9+ and C9+ EVs, albeit at varying levels despite receiving the same C9 dose. In conclusion, these results confirm increased esophageal C5b-9 formation during EAC development and demonstrate capability and heterogeneity in C5b-9 formation and shedding in BE and EAC cell lines following sublytic C9 exposure. Future work may explore the molecular mechanisms and pathogenic implications of the shed C5b-9+ EV.
- Subject
- complement system activation; exosome; extracellular vesicle (EV); microvesicle; terminal complement component (SC5b-9); SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1486242
- Identifier
- uon:51810
- Identifier
- ISSN:1664-3224
- Rights
- © 2022 Kolka, Webster, Lepletier, Winterford, Brown, Richards, Zelek, Cao, Khamis, Shanmugasundaram, Wuethrich, Trau, Brosda, Barbour, Shah, Eslick, Clemons, Morgan and Hill. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
- Language
- eng
- Full Text
- Reviewed
- Hits: 5055
- Visitors: 5066
- Downloads: 35
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 11 MB | Adobe Acrobat PDF | View Details Download |